“This approval is based on comprehensive results from two Phase 3 studies, which were recently published in Blood.In these studies, which included 441 patients who had either never been treated with a complement inhibitor before, or who had been stable on SOLIRIS, the efficacy of ULTOMIRIS administered every eight weeks was non-inferior to the efficacy
- Welcome to PNH Support!
News
1st December 2018
CONCORD (CoOrdiNated Care Of Rare Disease) Research Project
Genetic Alliance UK still have spaces available in upcoming focus groups for their research project CONCORD (CoOrdiNated Care Of Rare Disease). They are currently recruiting for focus groups for rare disease patients, carers and healthcare professionals. These focus groups are crucial to help the researchers understand the needs and concerns of both patients and healthcare
